Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2020-10-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于第四届监事会第十五次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of the resolution passed by the Supervisory Board regarding the review of the company's 2020 third quarter report. It states that the Supervisory Board has audited and approved the third quarter report, confirming its compliance and accuracy. The document itself does not contain the full third quarter report or detailed financial data, but rather the announcement of the Supervisory Board's approval of that report. The document length is short (677 characters), and it is an announcement of a meeting resolution related to the quarterly report, not the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about the quarterly report approval, not the Interim/Quarterly Report (IR) itself.
2020-10-26 Chinese
2020年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2020 Third Quarter Report" (2020年第三季度报告正文) for Teyi Pharmaceutical Group Co., Ltd. It contains detailed financial data and analysis for the third quarter of 2020, including key financial metrics, changes in assets and liabilities, shareholder information, and management commentary on performance and outlook. The presence of comprehensive financial statements and substantive financial data for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (8990 characters) and content confirm it is the report itself, not merely an announcement or certification. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2020
2020-10-26 Chinese
2020年前三季度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the first three quarters of 2020, including estimated net profit and earnings per share, with explanations about the impact of COVID-19 on sales and operations. It explicitly states it is an "业绩预告" (performance forecast) and mentions that the data is preliminary and unaudited, with final figures to be disclosed in the official third quarter report. The document length is about 2,000 characters, which is relatively short and primarily provides an earnings forecast rather than actual financial results or detailed financial statements. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results highlighting key figures and outlook. It is not a full Interim/Quarterly Report (IR) because it lacks substantive financial data and analysis, nor is it a Regulatory Filing or Report Publication Announcement since it contains actual forecast data rather than just a notice. Therefore, the best classification is Earnings Release (ER). 9M 2020
2020-10-14 Chinese
关于使用部分闲置募集资金进行现金管理到期赎回的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the use of idle raised funds for cash management and the maturity redemption of such investments. It details specific financial products, amounts, terms, and returns related to the company's cash management activities. The document is relatively short (1839 characters) and focuses on a specific financing activity rather than presenting comprehensive financial statements or a full report. It does not contain quarterly or annual financial results, nor does it discuss management changes, voting results, or legal matters. The content aligns with updates on company fundraising or capital management activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2020-10-12 Chinese
2020年第三季度可转换公司债券转股情况公告
Regulatory Filings Classification · 95% confidence The document is a quarterly announcement regarding the convertible bonds (可转换公司债券) of 特一药业集团股份有限公司, specifically detailing the conversion situation and share changes for the third quarter of 2020. It includes bond issuance details, conversion price adjustments, and shareholding changes due to bond conversions. The document is an announcement of bond conversion activity and shareholding changes, not a full financial report or earnings release. It is not a full interim or quarterly report (IR) because it lacks comprehensive financial statements or substantive financial data and analysis. It is also not a capital/financing update (CAP) in the sense of new fundraising or capital structure changes, but rather a specific bond conversion and shareholding change announcement. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement about bond conversion and shareholding changes that does not fit other specific categories.
2020-10-09 Chinese
关于非公开发行股票申请获得中国证监会受理的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the acceptance of its application for a non-public issuance of shares by the China Securities Regulatory Commission (CSRC). It states that the application materials have been reviewed and accepted for processing but the approval is still pending. The document is short (557 characters) and serves as an update on a capital raising process, specifically a non-public share issuance. It does not contain financial statements or detailed financial data, nor is it a full report. Therefore, it fits the category of Capital/Financing Update (CAP).
2020-10-09 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.